While monoclonal antibodies such as mepolizumab (targeting interleukin-5) and benralizumab (targeting the interleukin-5 receptor α subunit) have demonstrated efficacy in clinical trials for EGPA [14,15], their effectiveness remains limited. The gene discussed is IL5; the disease is eosinophilic granulomatosis with polyangiitis.